Business Context and Reporting Period
Anika Therapeutics, Inc. (ANIK) filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The company is a global leader in hyaluronic acid (HA) innovations, focusing on osteoarthritis (OA) pain management and orthopedic regenerative solutions. Following strategic divestitures of Arthrosurface (Oct 2024) and Parcus Medical (March 2025), the company has narrowed its focus to its core OA and regenerative portfolios. As of July 24, 2026, there were 13,382,966 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $32.6 million | $62.2 million |
| Gross Profit | $21.2 million | $40.2 million |
| Gross Margin | 65% | 65% |
| Net Income (Loss) | $3.3 million | ($1.7) million |
| Diluted EPS | $0.24 | ($0.13) |
| Cash and Cash Equivalents | $38.4 million (as of June 30, 2026) | N/A |
| Working Capital | $77.0 million | N/A |
| Debt | No outstanding borrowings on credit facility | N/A |
| Operating Cash Flow | N/A | ($5.5) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 16% ($4.4 million) for the quarter and 14% ($7.8 million) for the six months compared to the same periods in 2025. Growth was driven by higher sales volume in the OEM channel (primarily Johnson & Johnson MedTech) and increased Commercial Channel revenue from international OA products and regenerative solutions.
- Profitability Improvement: The company reported a net income of $3.3 million for the quarter, a significant turnaround from a net loss of $4.0 million in the prior year quarter. For the six months, the net loss narrowed to $1.7 million from $8.8 million in the prior year.
- Margin Expansion: Gross margin improved to 65% for both the three and six-month periods in 2026, up from 51% and 53% respectively in 2025, attributed to higher sales volume and improved manufacturing efficiency.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 10% for the quarter due to workforce reductions and lower legal fees, though they increased 14% for the six months due to $2.4 million in severance costs and accelerated stock-based compensation related to the CEO transition.
Guidance, Outlook, and Risks
- Regulatory Milestones: The company is advancing the New Drug Application (NDA) for Cingal in the U.S., having addressed FDA requirements regarding bioequivalence studies. A Premarket Approval (PMA) application for Hyalofast was submitted in October 2025; the company is responding to a deficiency letter received in January 2026.
- Capital Structure: On July 10, 2026, the company amended its credit facility to extend the maturity to July 2031 and maintain a $50 million revolving line of credit (expandable to $100 million). There were no outstanding borrowings as of June 30, 2026.
- Share Repurchases: The company completed its $30 million share repurchase program in April 2026 and is no longer actively repurchasing stock.
- Risks: Key risks include the timing of FDA approvals for Cingal and Hyalofast, dependence on a single significant customer (J&J MedTech, representing 50-53% of revenue), and the ability to realize deferred tax assets given historical operating losses.
Investor Verification Checklist
- Verify the status of the FDA deficiency letter response for the Hyalofast PMA application and the timeline for the Cingal NDA submission.
- Confirm the sustainability of the 65% gross margin given the mix of OEM vs. Commercial channel sales.
- Monitor the impact of the CEO transition and associated $3.3 million stock-based compensation charge on future SG&A trends.
- Assess the cash burn rate, noting the $5.5 million cash used in operating activities for the six months, driven by inventory build-up and receivables growth.
- Review the concentration risk associated with Johnson & Johnson MedTech, which accounts for over half of total revenue.